# **New Jersey Institute of Technology**

# Digital Commons @ NJIT

Chemical and Materials Engineering Syllabi

NJIT Syllabi

Fall 2024

# PHEN 601-101: Principles of Pharmaceutical Engineering

Marc Bernhardt

Follow this and additional works at: https://digitalcommons.njit.edu/cme-syllabi

#### **Recommended Citation**

Bernhardt, Marc, "PHEN 601-101: Principles of Pharmaceutical Engineering" (2024). *Chemical and Materials Engineering Syllabi*. 299.

https://digitalcommons.njit.edu/cme-syllabi/299

This Syllabus is brought to you for free and open access by the NJIT Syllabi at Digital Commons @ NJIT. It has been accepted for inclusion in Chemical and Materials Engineering Syllabi by an authorized administrator of Digital Commons @ NJIT. For more information, please contact digitalcommons@njit.edu.

## **PhEN 601**

# Syllabus Fall 2022

**Location:** Faculty Memorial Hall 412

Canvas: <a href="https://canvas.njit.edu/">https://canvas.njit.edu/</a>

Accessibility: The canvas accessibility statement is https://www.instructure.com/canvas/accessibility

Time: Tuesdays from 6:00 PM to 8:50 PM

Calendar: Below.

Instructor: Marc Bernhardt

Instructor Contact: mjb27@njit.edu

Instructor Feedback: Questions, comments and feedback to the instructor can be submitted in class, posted online in

Canvas or via email. The instructor's goal is to respond to all feedback within 2 business days,

usually within 24 hours.

Office Hours: There are no office hours; contact with the instructor is via email.

Prerequisites: An undergraduate degree in chemical engineering or mechanical engineering. Students who have not

completed such a degree may be enrolled on a case-by-case basis. See the NJIT Course Catalog and your

academic advisor for more details.

**Course Description:** This course provides an overview of the pharmaceutical industry, including basic information about drug discovery and development, FDA requirements and approval processes, drug dosage forms, and the role of key operational units in drug manufacturing processes. This course enables the students to: understand the role of the pharmaceutical industry in the global market and its implications; learn the fundamentals of the drug development cycle and the investment required to bring a drug to market; learn the most important drug manufacturing processes and the key elements of dosage formulation.

## **Learning Objectives:**

- Explain the role of the pharmaceutical industry in the global market and its implications.
- Apply the fundamentals of the drug development cycle.
- Compare and contrast the investment required to bring different drugs to market.
- Describe the most important drug manufacturing processes.
- Evaluate the pros and cons of different dosage forms.
- Create a strategy for designing a new drug.
- Document the role of the FDA in law enforcement, the legal requirements for marketing pharmaceuticals and the current the regulatory environment in which manufacturers and distributors function. By the end of this course the student will:
- Understand all of the key topics discussed.
- Be able to clearly integrate these topics into their total understanding of the pharmaceutical industry.
- Be familiar with and be able to effectively communicate using the specialized terminology (jargon) of the pharmaceutical industry.

 Apply their understanding of pharmaceutical engineering to analyze, evaluate and create drugs and medical devices.

Textbook: Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems 12<sup>th</sup> edition by Loyd. V. Allen, Jr. and

Timothy B. McPherson

**Navigating the course:** Each week the student is expected to:

Attend class as scheduled.

Read the assigned chapter(s) of the textbook.

Participate in discussions.

Stay current with the course materials and integrate new materials into their overall understanding of pharmaceutical engineering.

Prepare for the midterm exam and the final exam.

## What is expected from Students:

The course format was selected to facilitate learning in a with in class and online information.

The course includes several opportunities for students to demonstrate their mastery of the key topics.

Students are expected to dedicate at least 7.5 hours per week to the course during the semester.

Estimates:

#### **Grade Calculation:**

| Participation and Homework | 15% |
|----------------------------|-----|
| Midterm exam               | 35% |
| Final exam                 | 50% |

#### **Grade Policies:**

"D" Is not assigned in Graduate courses.

Each student must pass BOTH the midterm exam and the final exam with 70%, minimum.

If a student fails either the midterm or the final exam, the student will likely fail the course.

Exams will be administered in class using Canvas. Exams will be graded and the grades will be sent to students as soon as possible, typically within 2 weeks.

## **Participation Requirements:**

Students are expected to participate in discussions in class or online.

During the first two weeks of the course each student is required to upload a short (1 - 2 minute) video introducing themselves to the class and stating the reason that they are taking the course.

# **Exam Policies:**

2 HOURS, MAXIMUM.

**EXAMS ARE CLOSED BOOK** 

No books, No computers, No phones, No notes

The instructor will grade the exams.

**Policy for Make-Up Exams:** Pre-Approval by the instructor is REQUIRED.

#### **Academic Integrity**

ACADEMIC HONESTY AND INTEGRITY ARE PARAMOUNT AT NJIT. THE NJIT HONOR CODE WILL BE UPHELD.

ALL VIOLATIONS WILL IMMEDIATELY BE BROUGHT TO THE ATTENTION OF THE DEAN OF STUDENTS.

DON'T CHEAT.

DON'T COPY.

DON'T PLAGIARIZE.

## **Student Resources:**

The instructor.

The Teaching Assistant.

FDA.GOV

IST service desk for computer or connectivity issues: 973-596-2900

Academic Advising

Canvas student orientation.

Center for Counseling and Psychological Services (C-CAPS): (973) 596-3414

## **Calendar:**

# Fall 2024

| Date         | Topics                      | Ansel Chapter (12 <sup>th</sup> edition) | Notes |
|--------------|-----------------------------|--|-------|
| 3 September  | Introduction                | N/A                                      | 1     |
|              | Value Proposition           |  |       |
|              | Grade Policies              |  |       |
|              | Syllabus                    | N/A                                      | 2     |
|              | FDA.gov                     |  |       |
|              | Product Classification      | 1  | 3     |
|              | Medical Devices             | 1  | 4     |
|              | Cosmetics                   |  |       |
|              | Dietary Supplements         |  |       |
|              | Snake Oil                   | 1  | 5     |
|              | Homeopathy                  |  |       |
|              | Counterfeit Drugs           |  |       |
| 10 September | Pharmaceutical History      | 1  | 6     |
|              | U.S. Pharmacopeia           |  |       |
|              | The Future?                 |  |       |
|              | COVID Vaccines              | N/A                                      | 7     |
|              | Drug Development Funnel and | 2  | 8     |
|              | Contract Organizations      |  |       |
|              | "New" Drugs                 | 2  | 9     |
|              | Pre-Clinical Tests          | 2  | 10    |
|              | Clinical Trials             | 2  | 11    |
| 17 September | New Drug Applications       | 2  | 12    |
|              | Biological Drugs            | 2  | 13    |
|              | Prodrugs                    |  |       |
|              | Patents                     | N/A                                      | 14    |
|              | Copyrights                  |  |       |
|              | Trademarks                  |  |       |
|              | Receptors                   | 2  | 15    |
|              | Side Effects                |  |       |
|              | Drug Interactions           |  |       |

| 24 September | FDA Organization                       | 2        | 16  |
|--------------|--|----------|-----|
|              | History of Regulations                 |          |     |
|              | GMP                                    | 3        | 17  |
|              | FDA Investigations                     | N/A      | 18  |
|              | Controlled Substances Act              | N/A      | 19  |
|              | Packaging                              | N/A      | 20  |
|              | Labeling                               | 3        | 21  |
|              | Advertising                            | N/A      | 22  |
| 1 October    | Medication Errors                      | N/A      | 23  |
|              | Risk                                   |          |     |
|              | Drug Types / OTC                       | 3        | 24  |
|              | Goal Drug                              | 2        | 25  |
|              | ADME                                   | 2        | 26  |
|              | First Pass Effect                      |          |     |
|              | Serum Concentration Curves             | 5        | 27  |
| 8 October    | Placebo                                | 5        | 28  |
|              | Logical Fallacies                      |          |     |
|              | Drug Discovery                         | 2        | 29  |
|              | Drug Analogues                         |          |     |
|              | DPP-4 Discovery Example                | N/A      | 30  |
|              | Drug Names                             | ·        |     |
|              | Dosage Form Purpose                    | 4        | 31  |
|              | Dosage Form Issues                     |          |     |
|              | Preformulation Concerns                | 4        | 32  |
|              | Stability / Preservatives / Shelf Life | 4        | 33  |
|              | Excipients                             |          |     |
| 15 October   | Absorption                             | N/A      | 34  |
|              | Transport Phenomena                    |          |     |
|              | Compartmental Analysis                 |          |     |
|              | Bioavailability                        | 5        | 35  |
|              | Generics                               | N/A      | 36  |
|              | Clearance                              | 5        | 37  |
|              | Powders                                | 6        | 38  |
|              | Capsules                               | 7        | 39  |
|              | Tablets                                | 8        | 40  |
|              | Granulation                            | 6        | 41  |
|              | Tablet Coating                         | 8        | 42  |
|              | Oral Solid Dosage                      | 9        | 43  |
|              | Modified Release                       | 9        | 44  |
| 22 October   | Midterm Exam                           | N/A      | N/A |
| 29 October   | Ointments, Creams, Gels                | 10       | 45  |
|              | Transdermal Drug Delivery              | 11       | 46  |
|              | TDDS Advantages & Disadvantages        | 11       | 47  |
|              | Sanitary Equipment Design              | N/A      | 48  |
|              | Stainless Steel                        | N/A      | 49  |
|              | Welding                                | N/A      | 50  |
| 5 November   | No Class in person – Videos will be a  | ssigned. |     |

| 12 November | Water Purification              | N/A | 51  |
|-------------|---------------------------------|-----|-----|
|             | Water Regulations               | N/A | 52  |
|             | Water Purification Technologies | N/A | 53  |
|             | RO, DI, Distillation            | N/A | 54  |
|             | Suppositories                   | 12  | 55  |
|             | Phrma                           | N/A | 56  |
|             | Solutions                       | 13  | 57  |
| 19 November | Validation                      | N/A | 58  |
|             | Validation of Sterilization     | N/A | 59  |
|             | Disperse Systems                | 14  | 60  |
|             | Aerosols                        | 14  | 61  |
|             | Parenterals                     | 15  | 62  |
|             | Parenteral Packaging            | 15  | 63  |
|             | Infusion Pumps                  |     |     |
| 26 November | Sterilization                   | 15  | 64  |
|             | Biologicals                     | 16  | 65  |
|             | rDNA                            |     |     |
|             | Monoclonal Antibodies           | 19  | 66  |
|             | Diabetes                        | N/A | 67  |
|             | Research Project 2 groups and   | N/A | N/A |
|             | objective will be assigned.     |     |     |
|             | Follow On Biologicals           | 19  | 68  |
|             | Vaccines                        | 16  | 69  |
| 3 December  | Cancer Vaccines                 | N/A | 70  |
|             | Cold Chain                      |     |     |
|             | Facilities                      | N/A | 71  |
|             | Utilities                       | N/A | 72  |
|             | Process Gases                   |     |     |
|             | Cleanroom Design                | N/A | 73  |
|             | Cleanroom Regulations           | N/A | 74  |
| 10 December | Ophthalmics                     | 17  | 75  |
|             | Radiopharmaceuticals            | 18  | 76  |
|             | Novel Drug Delivery Ideas       | 20  | 77  |
|             | Quality                         | 21  | 78  |
| 17 December | Final Exam                      | N/A | N/A |